Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.
Acer Therapeutics has raised $1.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2023.
Acer Therapeutics's investors include Marathon Asset Management, TVM Capital Life Science, SWK Holdings.
Acer Therapeutics is headquartered in Newton, United States.
Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.
Acer Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Acer Therapeutics — Funding & Investors." VCBacked, June 26, 2023, https://www.vcbacked.co/company/acer-therapeutics. Accessed August 13, 2026.
VCBacked. (2023). Acer Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/acer-therapeutics
{{cite web |title=Acer Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/acer-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated